-
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumour
cphi-online
April 14, 2017
Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.
-
BMS and Apexigen to Evaluate Opdivo in Combination with APX005M in Advanced Solid Tumors
americanpharmaceuticalreview
April 12, 2017
Bristol-Myers Squibb Company and Apexigen, Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors.
-
The first overall survival data from the Phase 3 CheckMate -067 clinical trial
worldpharmanews
April 05, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial.
-
BMS receives positive CHMP opinion recommending Opdivo for head and neck cancer
cphi-online
March 29, 2017
Opdivo already approved by the EC for six indications in four distinct tumour types.
-
BMS Receives Positive CHMP Opinion Recommending Opdivo for the Treatment of Squamous Cell Cancer of
americanpharmaceuticalreview
March 27, 2017
Bristol-Myers Squibb Company has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo...
-
BMS, CytomX Expand Probody Pact
contractpharma
March 21, 2017
BMS gains worldwide rights to develop and commercialize as many as six additional oncology targets
-
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ The
americanpharmaceuticalreview
March 21, 2017
Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer...
-
BMS appoints Dr Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer
cphi-online
March 10, 2017
He succeeds Dr Francis Cuss, 62, who will retire from the company.
-
BMS Names EVP, CSO
contractpharma
March 10, 2017
Lynch brings 30 years of medical, management and leadership experience
-
The 5 Drug Giants That Could Snap Up a Struggling Bristol-Myers Squibb
BioSpace.com
March 06, 2017
Speculation on what company will make a bid for beleaguered Bristol-Myers Squibb (BMS) has ramped up since billionaire activist investor Carl Icahn acquired an undisclosed number of shares based on takeover rumors.